BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
BIIB LAWSUIT ALERT: Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR Newswire
NEW YORK
,
Feb. 24, 2022
/PRNewswire/ — Levi & Korsinsky, LLP notifies investors in
Biogen Inc.
(“Biogen” or the “Company”) (NASDAQ: BIIB) of a class action securities lawsuit.
CLASS DEFINITION:
The lawsuit seeks to recover losses on behalf of Biogen investors who were adversely affected by alleged securities fraud between
June 7, 2021
and
January 11, 2022
. Follow the link below to get more information and be contacted by a member of our team:
BIIB
investors may also contact
Joseph E. Levi, Esq.
via email at
[email protected]
or by telephone at (212) 363-7500.
CASE DETAILS:
The filed complaint alleges that defendants made false statements and/or concealed that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration (“FDA”) that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer’s disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer’s patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019; and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and that side-effects were dangerous and serious.
WHAT’S NEXT?
If you suffered a loss in Biogen during the relevant time frame, you have until
April 8, 2022
to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU:
If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees.
There is no cost or obligation to participate.
WHY LEVI & KORSINSKY:
Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in
the United States
.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY
10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/biib-lawsuit-alert-levi–korsinsky-notifies-biogen-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-301489281.html
SOURCE Levi & Korsinsky, LLP